Interim report Q1 2020
January - March · Net sales amounted to MSEK 793.6 (420.8). This corresponds to an increase of 89% for the period. The organic growth during the first quarter was 27%, currency impact -1% and 63% relates to the acquisition of Trimb in 2019 and the product portfolio acquired from Leo Pharma (see below). · EBIT amounted to MSEK 104.1 (87.4) corresponding to a 19% growth. · Adjusted EBITDA* amounted to MSEK 213.2 (153.0) corresponding to a 39% growth. This excluding non-recurring, costs related to the acquisition of the Leo Pharma portfolio totalling MSEK 3.9 (0.0). · The gross